Current Allergy and Asthma Reports

, Volume 13, Issue 4, pp 389–398 | Cite as

Accelerated Immunotherapy Schedules



Rush and cluster immunotherapy schedules are accelerated immunotherapy build-up schedules. A cluster immunotherapy schedule involves the patient receiving several allergen injections (generally 2–4) sequentially in a single day of treatment on nonconsecutive days. The maintenance dose is generally reached in 4–8 weeks. In rush immunotherapy protocols, higher doses are administered at 15- to 60-min intervals over a 1- to 3-day period until the maintenance dose is achieved. This review will serve as an update for accelerated immunotherapy schedules. The review will include recent investigations demonstrating the safety of cluster schedules in atopic dermatitis, pediatric patients, and inhalant allergen mixtures and an accelerated protocol utilizing an infusion pump for allergen delivery. There has also been further elucidation on the immunological changes which occur during accelerated immunotherapy. Finally, new studies analyzing systemic reaction risk factors are discussed.


Accelerated immunotherapy schedules Cluster immunotherapy Rush immunotherapy Subcutaneous immunotherapy Pre-medication Systemic reactions Large local reactions 


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    • Kim M-E, Kim J-E, Sung J-M, et al. Safety of accelerated schedules of subcutaneous allergen immunotherapy with house dust mite extract in patients with atopic dermatitis. J Korean Med Sci. 2011;26:1159–64. Study examining cluster in atopic dermatitis patients.PubMedCrossRefGoogle Scholar
  2. 2.
    Hernandez N, Ibero M, Ridao M, et al. Safety of specific immunotherapy using a depigmented and polymerized extract of Dermatophagoides pteronyssinus in children under five years of age. Allergol Immunopathol (Madr). 2011;39(5):267–70.CrossRefGoogle Scholar
  3. 3.
    Schubert R, Eickmeier O, Garn H, et al. Safety and immunogenicity of a cluster specific immunotherapy in children with bronchial asthma and mite allergy. Int Arch Allergy Immunol. 2009;148(3):251–60.PubMedCrossRefGoogle Scholar
  4. 4.
    • Copenhaver C, Parker A, Patch S. Systemic reactions with aeroallergen cluster immunotherapy in a clinical practice. Ann Allergy Asthma Immunol. 2011;107:441–7. Recent American study using the cluster schedule recommended in the practice parameter and analyzing systemic reaction risk factors to cluster immunotherapy.PubMedCrossRefGoogle Scholar
  5. 5.
    Pfaar O, Mosges R, Hormann K, Klimek L. Safety aspects of cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis. Eur Arch Otorhinolaryngol. 2010;267:245–50.PubMedCrossRefGoogle Scholar
  6. 6.
    • Davis LS, Bhutani S, Barnett SR, Khan D. Early gene expression changes with rush immunotherapy. Clin Mol Allergy. 2011;9:12. This study examined whole genome expression profiling to identify changes in mRNA expression of peripheral blood mononuclear cells from allergic patients undergoing RIT.PubMedCrossRefGoogle Scholar
  7. 7.
    Lou W, Wang C, Wang Y, et al. Enhancement of the frequency and function of IL-10-secreting type 1 T regulatory cells after 1 year of cluster allergen-specific immunotherapy. Int Arch Allergy Immunol. 2012;159:391–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Lou W, Wang C, Wang Y, et al. Responses of CD4(+) CD25(+) Foxp3(+) and IL-10-secreting type 1 T regulatory cells to cluster-specific immunotherapy for allergic rhinitis in children. Pediatr Allergy Immunol. 2012;23:140–9.PubMedCrossRefGoogle Scholar
  9. 9.
    • Sastre J, Vallejo L, Hernandez E, et al. Rush allergen subcutaneous immunotherapy administered with infusion pump. Ann Allergy Asthma Immunol. 2011;107:459–60. This study utilized a portable battery-operated infusion pump to deliver allergen subcutaneously to 81 allergic rhinitis subjects and analyzed systemic reaction rates. PubMedCrossRefGoogle Scholar
  10. 10.
    Justicia JL, Barasona MJ, Serrano P, et al. Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. J Investig Allergol Clin Immunol. 2006;17(6):386–92.Google Scholar
  11. 11.
    • Vegh AB, George KC, Lotfi-Emran S, et al. Total tryptase levels indicated risk for systemic reactions to rush immunotherapy and mast cell activation. Ann Allergy Asthma Immunol. 2011;106:342–3. This recent study found higher baseline tryptase levels in systemic reaction patients compared to non-SR patients undergoing RIT to an inhalant mixture.PubMedCrossRefGoogle Scholar
  12. 12.
    Nanda A, O’Connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol. 2004;114:1339–44.PubMedCrossRefGoogle Scholar
  13. 13.
    Tabar AI, Echechipia S, Garcia BE, et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol. 2005;116:109–18.PubMedCrossRefGoogle Scholar
  14. 14.
    Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol. 2008;121:1120–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Serrano P, Justicia JL, Sanchez C, et al. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study. Ann Allergy Asthma Immunol. 2009;102:247–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang L, Wang C, Han D, Wang X, Zhao Y, Liu J. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis. Int Arch Allergy Immunol. 2009;148:161–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Martinez-Canavate A, Eseverri JL, Rodenas R, et al. Evaluation of paediatric tolerance to an extract of Alternaria alternate under two treatment regimes. A multicentre study. Allergol Immunopathol. 2005;33(3):138–41.CrossRefGoogle Scholar
  18. 18.
    Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: A double-blind, placebo-controlled study. J Allergy Clin Immunol. 1996;97:1207–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Winther L, Malling HJ, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. II: side-effects. Allergy. 2000;55:327–35.Google Scholar
  20. 20.
    Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy. 2000;30:1423–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Subiza J, Feliu A, Subiza JL, et al. Cluster immunotherapy with a glutaraldehyde-modified mixture of grasses results in an improvement in specific nasal provocation tests in less than 2.5 months of treatment. Clin Exp Allergy. 2008;38(6):987–94.PubMedCrossRefGoogle Scholar
  22. 22.
    Pfaar O, van Twuijver E, Hecker H, et al. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation. Int Arch Allergy Immunol. 2012;160(4):420–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Colas C, Monzon S, Venturini M, Lezaun A. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J Allergy Clin Immunol. 2006;117:810–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Cox L. Accelerated immunotherapy schedules: review of efficacy and safety. Ann Allergy Asthma Immunol. 2006;97:126–38.PubMedCrossRefGoogle Scholar
  25. 25.
    Stewart GE, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol. 1992;90:567–78.PubMedCrossRefGoogle Scholar
  26. 26.
    Parmiani S, Fernandez T, Moreno C, Guardia P, Rico P. Clustered schedules in allergen-specific immunotherapy. Allergol Immunopathol. 2002;30(5):283–91.CrossRefGoogle Scholar
  27. 27.
    Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol. 2001;107:87–93.PubMedCrossRefGoogle Scholar
  28. 28.
    Mauro M, Russello M, Alesina R, et al. Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. Eur Ann Allergy Clin Immunol. 2006;38(1):31–4.PubMedGoogle Scholar
  29. 29.
    Harvey SM. Safety of rush immunotherapy to multiple aeroallergens in an adult population. Ann Allergy Asthma Immunol. 2004;92:414–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Portnoy J, Bagstad K, Kanarek H, Pacheco F, Hall B, Barnes C. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy Asthma Immunol. 1994;73:409–18.Google Scholar
  31. 31.
    Bernstein JA, Kagen SL, Bernstein DI, Bernstein IL. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis. Ann Allergy. 1994;73:423–8.PubMedGoogle Scholar
  32. 32.
    Roll A, Hofbauer G, Ballmer-Weber BK, Schmid-Grendelmeier P. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy. J Investig Allergol Clin Immunol. 2006;16:79–85.PubMedGoogle Scholar
  33. 33.
    Goldberg A, Confino-Cohen R. Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy. Ann Allergy Asthma Immunol. 2003;91:405–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Schiavino D, Nucera E, Pollastrini E, et al. Specific ultrarush desensitization in Hymenoptera venom-allergic patients. Ann Allergy Asthma Immunol. 2004;92:409–13.PubMedCrossRefGoogle Scholar
  35. 35.
    Tankersley MS, Walker RL, Butler WK, Hagan LL, Napoli DC, Freeman TM. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol. 2002;109:556–62.PubMedCrossRefGoogle Scholar
  36. 36.
    Dietrich JJ, Moore LM, Nguyen S, Hagan LL, Tankersley MS. Imported fire ant hypersensitivity: a 1-day rush immunotherapy schedule without premedication. Ann Allergy Asthma Immunol. 2009;103:535–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Bousquet J, Hejjaoui A, Dhivert H, Clauzel AM, Michel FB. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. III. Systemic reactions during the rush protocol in patients suffering from asthma. J Allergy Clin Immunol. 1989;83:797–802.PubMedCrossRefGoogle Scholar
  38. 38.
    Heijaioui A, Ferrando R, Dhivert H, Michel FB, Bousquet J. Systemic reactions occurring during immunotherapy with standardized pollen extracts. J Allergy Clin Immunol. 1992;89:925–33.CrossRefGoogle Scholar
  39. 39.
    Armentia-Medina A, Blanco-Quiros A, Martin-Santos JM, et al. Rush immunotherapy with a standardized Bermuda grass pollen extract. Ann Allergy Asthma Immunol. 1989;63:127–35.Google Scholar
  40. 40.
    Bousquet J, Braquemond P, Feinberg J, Guerin B, Maasch H, Michel FB. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy Asthma Immunol. 1986;56:456–9.Google Scholar
  41. 41.
    Bousquet J, Hejjaoui A, Skassa-Brociek W, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids, I: rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J Allergy Clin Immunol. 1987;80:591–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Moverare R, Vesterinen E, Metso T, Sorva R, Elfman L, Haahtela T. Pollen-specific rush immunotherapy: clinical efficacy and effects on antibody concentrations. Ann Allergy Asthma Immunol. 2001;86:337–42.PubMedCrossRefGoogle Scholar
  43. 43.
    Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134–40.PubMedCrossRefGoogle Scholar
  44. 44.
    Bousquet J, Becker WM, Hejjaoui A, et al. Differences in clinical and immunologic reactivity of patients allergic to grass pollens and to multiple-pollen species, II: efficacy of a double-blind, placebo-controlled, specific immunotherapy with standardized extracts. J Allergy Clin Immunol. 1991;88:43–53.PubMedCrossRefGoogle Scholar
  45. 45.
    Bousquet J, Guerin B, Dotte A, et al. Comparison between rush immunotherapy with a standardized allergen and an alum adjuved pyridine extracted material in grass pollen allergy. Clin Allergy. 1985;15:179–93.PubMedCrossRefGoogle Scholar
  46. 46.
    Bousquet J, Maasch HJ, Hejjaoui A, et al. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids, III: efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma. J Allergy Clin Immunol. 1989;84:546–56.PubMedCrossRefGoogle Scholar
  47. 47.
    Dolz I, Martinez-Cocera C, Bartolome JM, Cimarra M. A double-blind, placebo-controlled study of immunotherapy with grass-pollen extract Alutard SQ during a 3-year period with initial rush immunotherapy. Allergy. 1996;51:489–500.PubMedGoogle Scholar
  48. 48.
    Pfaar O, Urry Z, Robinson DS, et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy. 2012;67(2):272–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol. 1990;85:460–72.PubMedCrossRefGoogle Scholar
  50. 50.
    Hedlin G, Graff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts, V: effects of 3 years of treatment. J Allergy Clin Immunol. 1991;87:955–64.PubMedCrossRefGoogle Scholar
  51. 51.
    Hedlin G, Braff-Lonnevig V, Heilborn H, et al. Immunotherapy with cat- and dog-dander extracts, II: in vivo and in vitro immunologic effects observed in a 1-year double-blind placebo study. J Allergy Clin Immunol. 1986;77:488–96.PubMedCrossRefGoogle Scholar
  52. 52.
    Hedlin G, Heilborn H, Lilja G, et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol. 1995;96:879–85.PubMedCrossRefGoogle Scholar
  53. 53.
    Lilja G, Sundin B, Graff-Lonnevig V, et al. Immunotherapy with cat- and dog-dander extracts, IV: effects of 2 years of treatment. J Allergy Clin Immunol. 1989;83:37–44.PubMedCrossRefGoogle Scholar
  54. 54.
    Portnoy J, King K, Kanarek H, Horner S. Incidence of systemic reactions during rush immunotherapy. Ann Allergy Asthma Immunol. 1992;68:493–8.Google Scholar
  55. 55.
    Sharkey P, Portnoy J. Rush immunotherapy: experience with a one-day schedule. Ann Allergy Asthma Immunol. 1996;76:175–80.PubMedCrossRefGoogle Scholar
  56. 56.
    Brehler R, Klimek L, Pfaar O, et al. Safety of a rush immunotherapy build-up schedule with depigmented polymerized allergen extracts. Allergy Asthma Proc. 2010;31(3):e31–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Sturm G, Kranke B, Rudolph C, Aberer W. Rush Hymenoptera venom immunotherapy: a safe and practical protocol for high-risk patients. J Allergy Clin Immunol. 2002;110:928–33.Google Scholar
  58. 58.
    Patella V, Florio G, Giuliano A et al. Hymenoptera Venom Immunotherapy: Tolerance and efficacy of an ultrarush protocol versus a rush and a slow conventional protocol. Journal of Allergy 2012; article ID 192192, 8 pages.Google Scholar
  59. 59.
    Riccio AM, Saverino D, Pesce G, et al. Effects of different up-dosing regimens for Hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. PLoS One. 2012;7(6):e37980.PubMedCrossRefGoogle Scholar
  60. 60.
    Celesnik N, Vesel T, Rijavec M, et al. Short-term venom immunotherapy induces desensitization of FcεRI-mediated basophil response. Allergy. 2012;67(12):1594–600.PubMedGoogle Scholar
  61. 61.
    Patella V, Incorvaia C, Ricciardi L, et al. The adhesion molecule ICAM-1 is overexpressed in patients with Hymenoptera venom allergy and decreases after ultrarush venom immunotherapy. J Biol Regul Homeost Agents. 2011;25(3):465–8.PubMedGoogle Scholar
  62. 62.
    Cichocka-Jaroxz E, Dorynska A, Pietrzyk JJ, Spiewak R. Laboratory markers of mast cell and basophil activation in monitoring rush immunotherapy in bee venom-allergic children. Immunotherapy. 2011;3(8):1013–7.CrossRefGoogle Scholar
  63. 63.
    Reimers A, Hari Y, Muller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy. 2000;55:484–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Brockow K, Kiehn M, Riethmuller C, Vieluf D, Berger J, Ring J. Efficacy of antihistamine pretreatment in the prevention of adverse reactions to Hymenoptera immunotherapy: A prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol. 1997;100:458–63.PubMedCrossRefGoogle Scholar
  65. 65.
    Berchtold E, Maibach R, Muller U. Reduction of side effect from rush-immunotherapy with honey bee venom by pretreatment with terfenadine. Clin Exp Allergy. 1992;22:59–65.PubMedCrossRefGoogle Scholar
  66. 66.
    Muller U, Hari Y, Berchtold E. Premedication with antihistamines may enhance efficacy of specific-allergen immunotherapy. J Allergy Clin Immunol. 2001;107:81–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Muller U, Jutel M, Reimers A, et al. Clinical and immunologic effects of H1 antihistamine preventive medication during honeybee venom immunotherapy. J Allergy Clin Immunol. 2008;122:1001–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Ewbank PA, Murray J, Sanders K, Curran-Everett D, Dreskin S, Nelson HS. A double-blind, placebo-controlled immunotherapy dose–response study with standardized cat extract. J Allergy Clin Immunol. 2003;111:155–61.PubMedCrossRefGoogle Scholar
  69. 69.
    Wohrl S, Gamper S, Hemmer W, Heinze G, Stingl G, Kinaciyan T. Premedication with montelukast reduces local reactions of allergen immunotherapy. Int Arch Allergy Immunol. 2007;144:137–42.PubMedCrossRefGoogle Scholar
  70. 70.
    Heijaioui A, Dhivert H, Michel FB, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. IV. Systemic reactions according to the immunotherapy schedule. J Allergy Clin Immunol. 1990;85:473–9.CrossRefGoogle Scholar
  71. 71.
    • Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125:383–9. A prospective study which examined the effect of 16 weeks of treatment with omalizumab or placebo on the incidence of SR during cluster immunotherapy in 248 asthmatic subjects.PubMedCrossRefGoogle Scholar
  72. 72.
    Calabria CW, Cox L. Accelerated immunotherapy schedules and premedication. Immunol Allergy Clin N Am. 2011;31:251–63.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Dilley Allergy and Asthma Specialists LLPSan AntonioUSA

Personalised recommendations